Amedisys Inc (AMED)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	361,900	366,900	369,900	373,200	419,400	443,400	442,400	429,500	432,100	434,800	179,400	231,400	204,500	300,600	392,700	379,900	232,256	231,600	266,500	303,700
Total stockholders’ equity	US$ in thousands	1,066,510	1,039,910	1,006,780	1,079,120	1,051,570	1,015,740	985,646	966,758	931,351	905,264	874,272	788,153	809,224	756,205	720,851	679,197	640,450	602,564	561,781	520,246
Debt-to-equity ratio		0.34	0.35	0.37	0.35	0.40	0.44	0.45	0.44	0.46	0.48	0.21	0.29	0.25	0.40	0.54	0.56	0.36	0.38	0.47	0.58

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $361,900K ÷ $1,066,510K
= 0.34

Amedisys Inc.'s debt-to-equity ratio has shown some fluctuations over the past eight quarters. The ratio ranged from 0.37 to 0.46 during this period. A decreasing trend is observed from Q4 2022 to Q1 2023, where the ratio decreased from 0.41 to 0.37. However, there was a slight increase in the ratio in Q2 and Q3 2023, reaching 0.40 and 0.39, respectively.

Overall, the debt-to-equity ratio for Amedisys Inc. has stayed within a relatively narrow range, indicating a conservative level of financial leverage. A lower ratio suggests that the company relies more on equity financing rather than debt to fund its operations and growth. It is essential for investors and analysts to continue monitoring this ratio to assess the company's capital structure and financial risk.